Biosceptre International is a public, unlisted biotechnology company based in Sydney, Australia that is developing and commercializing antibody technologies to address a wide range of applications in the diagnosis and treatment of cancer.

P2X₇ is a major cellular receptor responsible for normal programmed cell death. Biosceptre’s technology is based on the fundamental discovery of a subtly changed form of P2X₇ that is found on all solid state cancer cells, but never on normal cells. Biosceptre has developed and patented a range of polyclonal, monoclonal and domain antibodies that bind to the non-functional form of P2X₇ (nf-P2X₇), but not to normal P2X₇.

Cancer is the second leading cause of death worldwide, and the disease with the highest unmet medical need.  Biosceptre’s technology has the potential to change the way cancer is diagnosed and treated worldwide, offering unparalleled benefits to patients, doctors and investors alike.

Read more about us or  to view a short animation of Biosceptre’s technology, click here.